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Monoclonal antibodies to novel myeloid antigens reveal human
neutrophil heterogeneity
(monocytes/myeloid celis/myeloid leukemia/hybridoma)
EDWARD D. BALL*t, ROBERT F. GRAZIANO*, Li SHEN*, AND MICHAEL W. FANGER*t
Departments of *Microbiology and tMedicine, Dartmouth Medical School, Hanover, New Hampshire 03756
Communicated by Oscar D. Ratnoff, May 17, 1982
ABSTRACT Three cytotoxic murine monoclonal antibodies
that recognize myeloid-specific antigens have been produced by
immunization with normal human neutrophils or myeloblasts from
a patient with acute myelomonocytic leukemia. Two ofthese, PMN
6 and PMN 29, are specific for neutrophils; the third monoclonal
antibody, AML-2-23, is reactive with the majority ofnormal mono-
cytes as well as a subpopulation of mature neutrophils. Although
neutrophils from all individuals tested expressed these antigens,
cytofluorographic analysis revealed that the percentage of cells
bearing the PMN 6 and AML-2-23 antigens varied among indi-
viduals. Significant additional heterogeneity in the density ofeach
antigen among antigen-bearing cells was also observed. All three
antibodies efficiently mediated complement-dependent cytotox-
icity of acute myelocytic leukemia cells yet were unreactive with
lymphocytic leukemia cells. Neutrophil cytotoxicity was mediated
by PMN 6 and PMN 29 but not by AML-2-23. On the other hand,
AML-2-23, but not PMN 6 or PMN 29, was cytotoxic for normal
monocytes and macrophages. These monoclonal antibodies may
be of value in the study of normal neutrophil function and differ-
entiation and may have clinical utility in diagnosis and therapy of
myeloid leukemia.
Neutrophilic granulocytes in the peripheral circulation appear
to be a morphologically homogenous, short-lived, fully differ-
entiated group of cells. These cells have a significant role in
nonspecific antibody- and complement-directed host defense.
Various correlates of neutrophil function have been identified
and used to monitor the activity of these cells and their abnor-
malities (1-4).. Although in vitro induction ofneutrophil activity
appears to mimic in vivo stimulation, different stimuli often in-
duce the same response, suggesting that a common pathway
may be activated through different cell surface receptors. Al-
ternatively, or in addition, different functional activities might
be associated with different subpopulations of neutrophils. In
fact, there is some evidence of functionally distinct neutrophil
subpopulations (5, 6).
A number of monoclonal antibodies reactive to antigens as-
sociated with human myeloid cells have recently been reported,
which may be useful in dissecting neutrophil biological activi-
ties. Several of these antibodies react with antigens associated
with both neutrophils and monocytes (7-9). Certain other
monoclonal antibodies are specific for and react with the entire
circulating neutrophil population (NCD 1, 1/12/13) (4, 10).
One ofthese antibodies, NCD 1, as well as one whose specificity
has not been defined (NCD 3), reacts with neutrophils and in-
hibits some but not all neutrophil functional correlates (4, 11).
NCD 1 blocks lysozomal enzyme release and chemotaxis,
whereas NCD 3 only inhibits N-formylmethionylleucylphenyl-
alanine-induced chemotaxis. The unique specificities of these
monoclonal antibodies suggest that there may be a large number
of antigens that are characteristic of myeloid cells.
In the present report we describe the reactivities of three
different myeloid-specific monoclonal antibodies-PMN 6,
PMN 29, and AML-2-23-which appear to be useful in studies
of neutrophils, neutrophil subpopulations, and myeloid leu-
kemias.
MATERIALS AND METHODS
Production ofHybridomas. Hybrid cells making monoclonal
antibodies to human neutrophils were prepared as described,
with neutrophils from normal donors or blast cells from a patient
with acute myelomonocytic leukemia used as immunogens (12,
13). Clones PMN 6, PMN 29, and AML-2-23, derived from two
different fusions, were selected for study on the basis of their
specific reactivity to neutrophils. Immunoglobulin class and
subclass of each monoclonal antibody were determined as de-
scribed (12).
Cells. Neutrophils used for immunizations and screenings
were isolated from the peripheral blood of normal donors.
Mononuclear cells were separated from neutrophils and eryth-
rocytes (RBC) by Ficoll/Hypaque gradient centrifugation (14).
RBC were separated from neutrophils by sedimentation in 2%
dextran and lysis by osmotic shock. Monocytes used for screen-
ing were prepared from the mononuclear fraction by adherence
to plastic Petri dishes pretreated with autologous serum for 15
min at 37°C. Both the monocyte and normal lymphocyte (non-
adherent mononuclear cell) preparations were stained for a-
naphthyl butyrate esterase (nonspecific esterase) in order to
assess their purity (15). In addition, all cell populations were
stained with Wright/Giemsa for morphologic analysis. Platelets
were prepared by centrifuging anticoagulated (0.4% sodium
citrate) whole blood for 10 min at 250 x g. The supernatant was
collected and the platelets were pelleted by centrifugation at
400 x g for 6 min. RBC were prepared by centrifuging anti-
coagulated whole blood and removing the supernatant and
buffy coat.
The human leukemia cell lines CCRF-CEM, Daudi, K562,
HL-60, and U937 were maintained in RPMI 1640 with 10% fetal
calf serum. CCRF-CEM, a lymphoblastoid cell line derived
from a patient with T-cell acute lymphocytic leukemia (16), and
Daudi, a Burkitt lymphoma cell line (17), were obtained from
the American Type Culture Collection. K562, a myeloid blast
cell line (18), was obtained from Bernice Schacter (University
Hospitals of Cleveland). The HL-60 cell line, derived from a
patient with acute promyelocytic leukemia (19), was a gift of
Robert Gallo (Laboratory of Tumor Immunology, National In-
stitutes of Health). The U937 cell line, derived from a patient
with histiocytic lymphoma and exhibiting some functional and
Abbreviations: RBC, erythrocytes; RIA, radioimmunoassay.
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morphologic characteristics ofmacrophages (20), was a gift from
Paul Guyre (Department of Physiology, Dartmouth Medical
School). The myeloid blast lines KG-i and KG-la were the gift
of P. Koeffler (Division of Hematology-Oncology, University
of California, Los Angeles) and were grown in a medium (Flow
Laboratories, McLean, VA) containing 20% fetal calfserum and
gentamicin (21, 22).
Cells from patients with acute myelocytic leukemia, acute
lymphocytic leukemia, or chronic lymphocytic leukemia were
separated from blood by Ficoll/Hypaque gradient centrifuga-
tion and cryopreserved at -70°C prior to use. After thawing,
the cells were assessed for viability by phase-contrast micros-
copy and acridine orange/ethidium bromide staining; they
were used only if >95% were viable. Two acute myelocytic leu-
kemia samples, AML-B and AML-C, were determined by mor-
phological and histochemical staining criteria to be myelomono-
cytic leukemias (M4 in the French, American, and British
classifications) (23). AML-A was a monocytic leukemia (M5) and
AML-D was an undifferentiated myeloid leukemia (Ml).
Binding and Cytotoxicity Assays. Binding of monoclonal an-
tibodies to cells was measured by replicate radioimmunoassay
(RIA) as described (12, 24). The ability of these monoclonal an-
tibodies to mediate complement-dependent cytotoxicity of leu-
kemia and normal cells was measured in a modified microcy-
totoxicity assay (12, 25).
Cytofluorographic Analysis. Cells were incubated at 107/
ml in 300 ,ul of hybridoma culture supernatant for 30 min at 4°C.
Supernatants from the parent myeloma line P3-X63Ag8 and
from a hybridoma secreting an IgM antibody reactive with an
irrelevant antigen were used as controls. The cells were washed
twice in phosphate-buffered saline containing 0.1% bovine
serum albumin and 0.05% sodium azide and incubated with 25
,ul of a 1: 10 dilution of affinity-purified fluorescein-conjugated
F(ab')2 goat anti-mouse immunoglobulin for 30 min at 4°C.
They were then washed and resuspended in 0.3 ml of the buff-
ered saline/albumin/azide. The Ortho (Westwood, MA) Cy-
tofluorograph system 50H with multichannel distribution ana-
lyzer 2103 and Ortho 2150 computer systems was used to
quantitate binding of the monoclonal antibodies to various cell
populations.
RESULTS
Initial Characterization of Myeloid-Specific Monoclonal
Antibodies PMN 6, PMN 29, and AML-2-23. The hybridomas
producing these antibodies were cloned twice by limiting di-
lution. The binding titer of the spent culture supernatant, de-
fined as the dilution that gave 50% of maximal binding to neu-
trophils in a RIA, was 1:64 for PMN 6, 1:32 for PMN 29, and
1:1024 for AML-2-23. PMN 6 and PMN 29 are IgM antibodies
and AML-2-23 is an IgG of the yl subclass.
The reactivity of these antibodies with normal peripheral
blood cells as measured by radio-binding assay is depicted in
Table 1. The antigens to which PMN 6 and PMN 29 bind are
expressed only on neutrophils (not on monocytes, lymphocytes,
RBC, or platelets). The AML-2-23 antigen is found on mono-
cytes and neutrophils but not on RBC or platelets. Cultured
monocytes that differentiated into macrophages continued to
express the AML-2-23 antigen to the same extent at 4 weeks
in culture. The low binding to lymphocytes was due to mono-
cyte contamination because AML-2-23-positive nonadherent
cells were positive for nonspecific esterase. Although the neu-
trophils of each individual tested expressed these three anti-
gens, a marked quantitative difference in expression of each
Table 1. Binding of monoclonal antibodies to normal peripheral
blood cells determined by radioimmunoassay
Binding, cpm/105 cells
Cell type PMN 6 PMN 29 AML-2-23
Neutrophils 1,200 ± 390 3,740 ± 470 550 ± 200
(640-1,550) (2,970-4,220) (440-880)
Monocytes* 0 0 1,290 ± 370
(830-1,820)
Lymphocytest 0 0 100 ± 7
(90-110)
RBC 0 0 0
Platelets 0 0 0
Numbers shown are means ± SD of counts bound to 105 cells from
five normal individuals; numbers in parentheses are ranges. The
counts (250-300 cpm) bound by control hybridoma supernatants were
subtracted.
* Prepared by adherence to plastic; 85-90% of adherent cells were pos-
itive for nonspecific esterase and were morphologically consistent
with monocytes.
t Preparations contained up to 12% cells staining positively for non-
specific esterase. Nonadherent mononuclear cells positive for AML-
2-23 by indirect immunofluorescence were isolated by using the cell
sorter and were determined to be 100% monocytes based on nonspe-
cific esterase staining.
Cytofluorographic Analysis. Fluorescence staining analyzed
by cytofluorography indicated that 68-85% of monocytes and
72-91% of neutrophils bore the antigen recognized by mono-
clonal antibody AML-2-23 (Table 2). The small percentage of
cells staining with AML-2-23 in the lymphocyte (nonadherent
mononuclear cell) fraction were isolated by fluorescent cell sort-
ing and found to be 100% monocytes by nonspecific esterase
staining (data not shown). The fluorescence intensity profile of
this antibody on monocytes (Fig. LA) indicated that the majority
of cells showed very intense staining. AML-2-23 showed a dif-
ferent fluorescence profile on neutrophils (Fig. 1B) and did not
stain any neutrophils as intensely as it did monocytes.
The antigen recognized by monoclonal antibody PMN 29 was
expressed on >95% of neutrophils but not on lymphocytes and
monocytes (Tables 1 and 2). As indicated by RIA (Table 1), PMN
6 reacted only with neutrophils and not with lymphocytes or
monocytes. Moreover, its binding was limited to 58-95% of
neutrophils in different individuals (Table 2). Neutrophils
stained with PMN 29 showed a wide range of fluorescence in-
tensities (Fig. 2A). The majority of neutrophils stained with
PMN 6 occurred in the lower fluorescence range and yet the
Table 2. Reactivity of monoclonal antibodies with normal
peripheral blood cells determined by flow cytometry
% cells stained
Cell population PMN 6 PMN 29 AML-2-23
Neutrophils
Donor 1 95 96 72
Donor 2 60 95 75
Donor 3 58 96 75
Donor 4 75 95 91
Donor 5 93 99 85
Monocytes*
Donor 1 0 0 82
Donor2 0 0 68
Donor3 0 0 84
Donor 4 0 0 85
antigen was found among individuals. Similarly, the expression
of AML-2-23 antigen on monocytes showed wide variation
among individuals.
Results are expressed as the percentage of cells staining, correct for
background, by indirect immunofluorescence.
* See * in Table 1.
Immunology: Ball et al.
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FIG. 1. Reactivity of monoclonal antibody AML-2-23 to monocytes
(A) and neutrophils (B) revealed by indirect immunofluorescence and
cytofluorography. Patterns of staining are shown relative to a control
sample (P3) treated with supernatant containing IgG1 from the P3-
X63Ag8 myeloma.
total range offluorescence intensities observed with PMN 6 was
also very broad.
Mean intensity of fluorescence staining was examined for
comparison ofaverage quantity ofantigen on cells (Table 3). The
antigen detected by AML-2-23 was expressed in far greater
amounts on monocytes than on neutrophils from the same in-
dividual. Neutrophils from different donors also expressed
varying mean amounts of this antigen. This variation was also
observed with staining by antibody PMN 6 but not with PMN
29.
Cells from the lymphoblastoid lines CCRF-CEM and Daudi
did not stain with either antibody (Table 4). A large percentage
of cells of the HL-60 line, however, were positive for PMN 6
and PMN 29 and had mean fluorescence intensities similar to
those obtained with positively stained neutrophils. A smaller
percentage of cells also stained with AML-2-23 but with a mean
fluorescence intensity greater than that of AML-2-23-positive
neutrophils. Only PMN 29 stained the U937, K562, and KG-
1 lines.
CONTROL A
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FIG. 2. Indirect immunofluorescence staining of neutrophils by
monoclonal antibodies PMN 29 (A) and PMN 6 (B), studied by cyto-
fluorography. Staining patterns are shown relative to a control sample
treated with a monoclonal IgM of irrelevant specificity.
Complement-Dependent Cytotoxicity. Monoclonal antibod-
ies PMN 6 and PMN 29 efficiently mediated complement-de-
pendent cytotoxicity ofneutrophils, selected leukemia cell sam-
ples, and the HL-60 cell line (Tables 5 and 6). PMN 6 was
consistently cytotoxic to 30-75% of neutrophils from different
individuals whereas PMN 29 was cytotoxic to virtually 100% of
neutrophils from all individuals tested. AML-2-23 mediated
cytotoxicity against normal monocytes, leukemia samples with
myelomonocytic or monocytic morphology (12), and the HL-60
cell line to a titer of 2.5 x iO-'. However, despite binding to
neutrophils, AML-2-23 did not mediate cytotoxicity of these
cells. PMN 6 and PMN 29 were also cytotoxic to myelomono-
cytic leukemia samples. None of these antibodies reacted with
lymphocytic leukemia cells.
DISCUSSION
In this report we describe the properties of three monoclonal
antibodies specific to myeloid cells. Two are specific for neu-
trophils, PMN 6 and PMN 29; the third, AML-2-23, is specific
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Table 3. Degree of binding of monoclonal antibodies to
neutrophils and monocytes as determined by
flow cytometry
Mean fluorescence intensity
Cell type PMN 6 PMN 29 AML-2-23
Neutrophils
Donor 1 370 710 180
Donor 2 160 620 150
Donor 3 100 550 95
Donor 4 190 620 205
Donor 5 150 490 50
Monocytes
Donor 1 0 0 >1,000
Donor 2 0 0 >1,000
Donor 3 0 0 >1,000
Donor 4 0 0 >1,000
Mean fluorescence intensity was calculated as follows:
mean = - E(Nx * x)N
in which N = total number of cells; Nx = number of cells in channel
x; x = channel number. Results are expressed as mean fluorescence
of the experimental sample minus the mean fluorescence of the
control.
for an antigen present on both neutrophils and monocytes. All
are unreactive with lymphocytes, RBC, and platelets. More
detailed analysis by cytofluorography indicates that PMN 29
binds to virtually all neutrophils butPMN 6 and AML-2-23 react
with a subpopulation of these cells. AML-2-23 also binds to
68-85% of normal human monocytes. None of these antibodies
reacts with previously described neutrophil alloantigens (26)
because all individuals studied expressed each antigen.
Two other human neutrophil-specific monoclonal antibodies
have been reported to date. One identifies an antigen (My-i)
present on neutrophils, bone marrow neutrophil precursors,
and blast cells ofsome patients with myeloid leukemia (10). The
other monoclonal antibody (NCD 1) was found to inhibit neu-
trophil chemotaxis and degranulation (4). NCD 3, a monoclonal
antibody of undefined specificity, has been reported to inhibit
N-formylmethionylleucylphenylalanine-induced chemotaxis of
neutrophils (11). Like PMN 29, all of these antibodies bind to
>95% of neutrophils. Although certain differences in the bind-
ing patterns ofthese antibodies exist, insufficient data are avail-
able to permit definitive comparison of their reactivities.
Monoclonal antibody AML-2-23 recognizes a determinant
shared by both monocytes and neutrophils, as do a number of
other monoclonal antibodies (4, 7-9, 27, 28). In addition, some
hybridoma-derived antibodies that react only with monocytes
Table 4. Binding of monoclonal antibodies to cell lines
determined by indirect immunofluorescence and
flow cytometry
% cells stained
Cell line PMN 6 PMN 29 AML-2-23
CCRF-CEM 0 0 0
Daudi 0 0 0
HL-60 57 80 14
U937 0 12 0
K562 0 11 0
KG-la 0 0 0
KG-1 0 18 0
Table 5. Complement-dependent cytotoxicity of normal cell
populations mediated by monoclonal antibodies
% cytotoxicity
Cell population
Neutrophils
Donor 1
Donor 2
Donor 3
Donor 4
Donor 5
Monocytes
Donor 1
Donor 2
Donor 3
Donor 4
Donor 5
PMN 6 PMN 29
50-75
30-50
30-50
30-50
30-50
0
0
0
0
0
>90
>90
>90
>90
>90
0
0
0
0
0
AML-2-23
0
0
0
0
0
>90
>90
>90
>90
50-75
Cytotoxicity was estimated by dye exclusion in microtiter wells.
Lymphocytes were not killed by any of these antibodies.
have been described (9, 29, 30). Most of these antibodies react
with the majority of myelomonocytic and monocytic leukemia
cells and some myelocytic blasts. One antibody, MY8, prepared
by Griffin et aL (7) reacts with about 78% ofadherent peripheral
blood mononuclear cells and 72% of neutrophils. Although this
resembles the reactivity of AML-2-23, some differences exist.
MY8 binds strongly to the U937 and HL-60 cell lines whereas
AML-2-23 only reacts significantly with the HL-60 cell line.
This suggests recognition of different antigens, but definitive
proof requires characterization of both the MY8 and AML-2-23
antigens. Sufficient qualitative and quantitative differences in
reactivity also exist between AML-2-23 and other monoclonal
antibodies to suggest that AML-2-23 binds to a determinant not
previously recognized.
The fluorescence intensity profile of the AML-2-23 antigen
on monocytes and neutrophils indicates a major difference be-
tween the two cell types in the expression ofthis antigen. Large
amounts of the AML-2-23 antigen appear to be present on the
majority of monocytes although some monocytes express little
of this antigen. Neutrophils also are not homogeneous in their
display ofthe AML-2-23 antigen. Similarly, the antigen defined
by PMN 6 is not detectable on up to 40% of neutrophils but is
present in high quantity on the others. Antibodies AML-2-23
and PMN 6 thus detect significant differences in cell surface
antigen display among neutrophils which may reflect matura-
Table 6. Complement-dependent cytotoxicity of leukemia cells
and cell lines mediated by monoclonal antibodies
% cytotoxicity
Cell population*
HL-60*
AML-A
B
C
D
ALL-A
B
C
CLL-A
B
Hairy cell
leukemia
PMN 6 PMN 29 AML-2-23
50-75
ND
>90
>90
0
0
0
0
0
0
0
>90
ND
>90
>90
0
0
0
0
0
0
0
15-30
>90
>90
>90
0
0
0
0
0
0
0
Cytotoxicity was estimated by dye exclusion in microtiter wells. ND,
not done.
* None of these monoclonal antibodies mediated cytotoxicity of the
KG-la, CCRF-CEM, Daudi, K562, and U937 cell lines.
Results are expressed as the percentage of cells stained by mono-
clonal antibodies over background staining with an irrelevant anti-
body of the same immunoglobulin class and subclass.
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tion in the circulation or functional diversity or both. The
amount of antigen PMN 29 varied widely among neutrophils
yet was expressed on these cells in greater quantity than the
antigens bound by AML-2-23 and PMN 6. Based upon studies
of myeloid cell lines, normal neutrophils, and monocytes, each
of the three antigens appears to have a characteristic quanti-
tative and qualitative distribution on myeloid cells at various
stages of maturation. Some immature blasts ofthe KG-la, KG-
1, and K562 cell lines only express the PMN 29 antigen whereas
the more differentiated cells of the HL-60 line display all three
antigens to some degree. In contrast to the HL-60 line, a larger
percentage of mature normal neutrophils express the PMN 29
and AML-2-23 antigens; the number of PMN 6-positive cells
is the same in both cases. Studies on differentiation of the HL-
60 cell line with dimethyl sulfoxide and phorbol esters (31) may
provide more insight into the relative expression of these an-
tigens on myeloid precursors at distinct stages of morphologic
development.
The selective reactivity and cytotoxicity of these monoclonal
antibodies to many myeloid leukemia cell samples may prove
to be important in the identification and subgrouping ofmyeloid
leukemia cells. Based on these and other studies (12, 24), it
would appear that blast cells from many patients with acute
myelocytic leukemia bear at least two ofthese myeloid antigens
whereas all lymphocytic leukemia samples studied have been
negative. PMN 6 and PMN 29 were found to mediate comple-
ment-dependent cytotoxicity in two cases of acute myelocytic
leukemia studied whereas AML-2-23 selectively mediated lysis
in six of six acute myelomonocytic and acute monocytic leu-
kemia cell samples (12) but not in an undifferentiated myel-
ogenous leukemia (AML-D). Thus, all three ofthese antibodies
show considerable promise for both the diagnosis and treatment
of leukemia. Furthermore, these monoclonal antibodies have
considerable potential for investigations of neutrophils in dis-
ease states. Patients with congenital diseases in which disorders
ofnormal neutrophil function are manifest (chronic granuloma-
tous disease and Chediak-Higashi syndrome) or diseases in
which there is a marked propensity for infection (diabetes mel-
litus or sickle cell anemia), for example, may have altered pro-
portions of neutrophil subpopulations that reflect their func-
tional capacities.
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